Rivaroxaban in Thrombotic Antiphospholipid Syndrome
NCT02157272
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
121
Enrollment
OTHER
Sponsor class
Stopped
Unbalance in the composite endpoint between arms.
Conditions
Antiphospholipid Syndrome
Interventions
DRUG:
Experimental: Rivaroxaban
Sponsor
University of Padova